Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma. A nurse practitioner discusses her role in caring for ...
Inavolisib plus palbociclib and fulvestrant was approved for the treatment of PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer. The FDA approved inavolisib ...